Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
08:54pm, Tuesday, 10'th Feb 2026
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
08:30pm, Tuesday, 10'th Feb 2026
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates
06:25pm, Tuesday, 10'th Feb 2026
Exelixis (EXEL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.55 per share a year ago.
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 10'th Feb 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key cor
4 Discounted PEG Value Stocks to Boost Your Portfolio's Health
10:35am, Tuesday, 10'th Feb 2026
Discounted PEG screen highlights four value stocks, led by healthcare. One can pick Exelixis, alongside DaVita, Phibro and Allison Transmission.
BridgePort Financial Solutions LLC Takes $517,000 Position in Exelixis, Inc. $EXEL
03:58am, Tuesday, 10'th Feb 2026
BridgePort Financial Solutions LLC acquired a new position in Exelixis, Inc. (NASDAQ: EXEL) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
2 Intriguing Medical Stocks to Watch as Q4 Results Approach: EXEL, GILD
08:16pm, Monday, 09'th Feb 2026
With their Q4 results approaching after-market hours on Tuesday, February 10, Exelixis (EXEL) and Gilead Sciences (GILD) are two top-performing medical stocks to consider.
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of “Hold” by Brokerages
04:44am, Monday, 09'th Feb 2026
Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) has received an average rating of "Hold" from the twenty-four analysts that are presently covering the company, Marketbeat Ratings reports. Two investme
Exelixis, Inc. $EXEL Shares Sold by Principal Financial Group Inc.
04:29am, Sunday, 08'th Feb 2026
Principal Financial Group Inc. decreased its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 3.8% during the undefined quarter, according to its most recent filing with the Securities and Excha
BI Asset Management Fondsmaeglerselskab A S Raises Holdings in Exelixis, Inc. $EXEL
03:20am, Saturday, 07'th Feb 2026
BI Asset Management Fondsmaeglerselskab A S increased its position in Exelixis, Inc. (NASDAQ: EXEL) by 126.0% in the undefined quarter, according to its most recent filing with the SEC. The fund owned
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
01:45pm, Thursday, 05'th Feb 2026
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Wednesday, 04'th Feb 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Tuesday, 03'rd Feb 2026
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:50am, Tuesday, 03'rd Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Exelixis (EXEL) Stock?
10:40am, Tuesday, 03'rd Feb 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
